Principal Financial Group Inc Karuna Therapeutics, Inc. Transaction History

Principal Financial Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$161.01 - $317.85 $157,306 - $310,539	-977 Reduced 10.99%	7,910 $2.5 Million
Q3 2023 Nov 02, 2023	SELL	$164.66 - $218.08 $467,469 - $619,129	-2,839 Reduced 24.21%	8,887 $1.5 Million
Q2 2023 Aug 07, 2023	BUY	$176.32 - $240.22 $142,995 - $194,818	811 Added 7.43%	11,726 $2.54 Million
Q1 2023 May 09, 2023	BUY	$161.33 - $204.36 $483 - $613	3 Added 0.03%	10,915 $1.98 Million
Q4 2022 Feb 09, 2023	BUY	$191.53 - $236.82 $591,636 - $731,536	3,089 Added 39.49%	10,912 $2.14 Million
Q3 2022 Nov 09, 2022	BUY	$123.79 - $277.42 $42,088 - $94,322	340 Added 4.54%	7,823 $1.76 Million
Q2 2022 Aug 10, 2022	BUY	$93.97 - $143.33 $1,973 - $3,009	21 Added 0.28%	7,483 $947,000
Q1 2022 May 09, 2022	BUY	$98.9 - $132.37 $16,714 - $22,370	169 Added 2.32%	7,462 $946,000
Q4 2021 Feb 09, 2022	SELL	$110.64 - $159.4 $318,975 - $459,550	-2,883 Reduced 28.33%	7,293 $956,000
Q3 2021 Nov 09, 2021	BUY	$101.2 - $125.87 $39,468 - $49,089	390 Added 3.99%	10,176 $1.25 Million
Q2 2021 Aug 10, 2021	BUY	$107.45 - $135.95 $54,047 - $68,382	503 Added 5.42%	9,786 $1.12 Million
Q1 2021 May 10, 2021	SELL	$95.46 - $133.08 $20,619 - $28,745	-216 Reduced 2.27%	9,283 $1.12 Million
Q4 2020 Feb 08, 2021	BUY	$75.23 - $109.23 $309,797 - $449,809	4,118 Added 76.53%	9,499 $965,000
Q3 2020 Nov 06, 2020	SELL	$71.31 - $109.74 $201,308 - $309,796	-2,823 Reduced 34.41%	5,381 $416,000
Q2 2020 Aug 05, 2020	BUY	$62.14 - $117.21 $509,796 - $961,590	8,204 New	8,204 $914,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.